OTCPK:CMOPF (Ireland)
Â
Registered Shares
$
73.5
(0%)
12:08 AM EST
Business Description
Cosmo Pharmaceuticals NV
NAICS : 325412
SIC : 2834
ISIN : NL0011832936
Share Class Description:
CMOPF: Registered SharesDescription
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 91.69 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 22.09 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.35 | |||||
| Beneish M-Score | -2.89 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.1 | |||||
| 3-Year EBITDA Growth Rate | 34.5 | |||||
| 3-Year EPS without NRI Growth Rate | 19 | |||||
| 3-Year FCF Growth Rate | 43.1 | |||||
| 3-Year Book Growth Rate | -6.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 28.77 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.72 | |||||
| 9-Day RSI | 58.67 | |||||
| 14-Day RSI | 60.07 | |||||
| 3-1 Month Momentum % | 1.55 | |||||
| 6-1 Month Momentum % | -25.58 | |||||
| 12-1 Month Momentum % | 2.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.85 | |||||
| Quick Ratio | 4.48 | |||||
| Cash Ratio | 3.52 | |||||
| Days Inventory | 218.21 | |||||
| Days Sales Outstanding | 53.59 | |||||
| Days Payable | 181.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.96 | |||||
| Dividend Payout Ratio | 0.25 | |||||
| Forward Dividend Yield % | 2.96 | |||||
| 5-Year Yield-on-Cost % | 2.96 | |||||
| 3-Year Average Share Buyback Ratio | -3.6 | |||||
| Shareholder Yield % | 19.2 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.46 | |||||
| Operating Margin % | 47.18 | |||||
| Net Margin % | 37.8 | |||||
| FCF Margin % | 52.69 | |||||
| ROE % | 15.49 | |||||
| ROA % | 10.84 | |||||
| ROIC % | 13.16 | |||||
| 3-Year ROIIC % | -47.46 | |||||
| ROC (Joel Greenblatt) % | 189.63 | |||||
| ROCE % | 16.35 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.8 | |||||
| Forward PE Ratio | 12.33 | |||||
| PE Ratio without NRI | 15.93 | |||||
| Shiller PE Ratio | 25.26 | |||||
| PS Ratio | 5.96 | |||||
| PB Ratio | 2.2 | |||||
| Price-to-Tangible-Book | 10.94 | |||||
| Price-to-Free-Cash-Flow | 11.27 | |||||
| Price-to-Operating-Cash-Flow | 9.41 | |||||
| EV-to-EBIT | 10.76 | |||||
| EV-to-Forward-EBIT | 8.96 | |||||
| EV-to-EBITDA | 9.27 | |||||
| EV-to-Forward-EBITDA | 7.85 | |||||
| EV-to-Revenue | 5.28 | |||||
| EV-to-Forward-Revenue | 3.97 | |||||
| EV-to-FCF | 9.98 | |||||
| Price-to-GF-Value | 0.94 | |||||
| Price-to-Projected-FCF | 4.13 | |||||
| Price-to-Median-PS-Value | 0.62 | |||||
| Price-to-Graham-Number | 2.78 | |||||
| Price-to-Net-Current-Asset-Value | 24.92 | |||||
| Earnings Yield (Greenblatt) % | 9.29 | |||||
| FCF Yield % | 8.91 | |||||
| Forward Rate of Return (Yacktman) % | 21.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CMOPF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cosmo Pharmaceuticals NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 200.214 | ||
| EPS (TTM) ($) | 4.631 | ||
| Beta | 0.29 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 36.88 | ||
| 14-Day RSI | 60.07 | ||
| 14-Day ATR ($) | 0.469342 | ||
| 20-Day SMA ($) | 72.468 | ||
| 12-1 Month Momentum % | 2.61 | ||
| 52-Week Range ($) | 66.9252 - 95 | ||
| Shares Outstanding (Mil) | 16.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cosmo Pharmaceuticals NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cosmo Pharmaceuticals NV Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cosmo Pharmaceuticals NV Frequently Asked Questions
What is Cosmo Pharmaceuticals NV(CMOPF)'s stock price today?
The current price of CMOPF is $73.50. The 52 week high of CMOPF is $95.00 and 52 week low is $66.93.
When is next earnings date of Cosmo Pharmaceuticals NV(CMOPF)?
The next earnings date of Cosmo Pharmaceuticals NV(CMOPF) is .
Does Cosmo Pharmaceuticals NV(CMOPF) pay dividends? If so, how much?
The Dividend Yield %  of Cosmo Pharmaceuticals NV(CMOPF) is 2.96% (As of Today), Highest Dividend Payout Ratio of Cosmo Pharmaceuticals NV(CMOPF) was 1.1. The lowest was 0.25. And the median was 0.91. The  Forward Dividend Yield % of Cosmo Pharmaceuticals NV(CMOPF) is 2.96%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers